Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2002-07-16
2004-06-22
Raymond, Richard L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C562S606000
Reexamination Certificate
active
06753349
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method of preparing oligomeric valproic acid compounds, especially a method of preparing selected oligomeric valproic acid compounds, without the addition of a solvent. Valproic acid is also known as 2-propylpentanoic acid, 2-propylvaleric acid or di-n-propylacetic acid. The term valproic acid is used hereafter.
BACKGROUND OF THE INVENTION
Valproic acid and oligomeric compounds are known per se. Valproic acid, sodium valproate and the oligomeric 1:1 compound of sodium valproate and valproic acid, called divalproex sodium, are active ingredients for the medicinal treatment of epileptic fits, cramp and migraine. Valproic acid is liquid at room temperature and is therefore unsuitable for the preparation of solid pharmaceutical formulations such as tablets. Sodium valproate is solid at room temperature but is very hygroscopic, which makes it very difficult to prepare solid pharmaceutical formulations for oral administration. Divalproex sodium is less hygroscopic, but the compound has a tendency to form lumps and become encrusted on prolonged storage.
SUMMARY OF THE INVENTION
The oligomeric valproic acid compounds described below, with different stoichiometries and solvates, represent possible ways of formulating valproic acid which exhibit said disadvantages to a considerably reduced extent, if at all. It is therefore of interest to be able to prepare such compounds in the simplest possible manner. In particular, it has been found that oligomeric compounds of sodium valproate and valproic acid can be prepared without the addition of a solvent to the reaction mixture, which is ecologically and economically advantageous.
The method according to the invention also has the advantage that lengthy and energy-intensive drying processes can be avoided and environmentally relevant aspects, for example minimization of resources, saving of raw materials and energy or waste reduction, can be taken into account. In particular, the method according to the invention enables the active ingredients to be prepared without drying, under mild conditions and with the avoidance of decomposition processes due to temperature.
At the same time, the method according to the invention offers doctors and patients the opportunity to select their preferred active ingredients from the large number of different, equally potent compounds of valproic acid and valproic acid salts, all of these active ingredients having been prepared by processes identical per se.
One particular advantage of the present invention is that the method according to the invention makes it possible to prepare compounds with selected stoichiometries, i.e., with selected proportions of valproic acid salt and valproic acid, which has hitherto been impossible for these compositions via crystallization from organic solvents. Another advantage of the method according to the invention is that it dispenses with the use of sodium valproate as a hygroscopic sodium source.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention relates in particular to a method of preparing compounds containing at least one molecule of valproic acid salt and at least one molecule of valproic acid, the valproic acid salt being an alkali metal or alkaline earth metal salt, characterized in that valproic acid is reacted directly with the calculated amount of the appropriate alkali metal carbonate or alkaline earth metal carbonate and/or the calculated amount of the appropriate alkali metal bicarbonate or alkaline earth metal bicarbonate, without the addition of a solvent, at a temperature above the melting point of valproic acid.
The reaction temperature is preferably 50° C. to 250° C. and particularly preferably 70° C. to 180° C., the carbon dioxide and water formed in the reaction being removed continuously from the reaction mixture. The valproic acid reacts directly and completely with the carbonate (e.g. Na
2
CO
3
, CaCO
3
) or the bicarbonate (e.g. LiHCO
3
, Ca(HCO
3
)
2
) to form CO
2
and water. If the compound is to be prepared as a hydrate, the calculated amount of water is added to the product, preferably after the reaction has ended.
An alkali metal salt of valproic acid is preferably the lithium, sodium, potassium or rubidium salt and particularly preferably the sodium or potassium salt. An alkaline earth metal salt of valproic acid is preferably the magnesium, calcium, strontium or barium salt and particularly preferably the magnesium or calcium salt.
The compounds according to the present invention, which contain at least one molecule of valproic acid salt and at least one molecule of valproic acid, have general formula (I):
[(CH
3
CH
2
CH
2
)
2
CH—C(O)OMe]
m
.[(CH
3
CH
2
CH
2
)
2
CH—C(O)OH]
n
.xH
2
O (I)
in which
Me is Li
+
, Na
+
, K
+
, Rb
+
, Mg
2+
, Ca
2+
, Sr
2+
or Ba
2+
, preferably Na
+
, K
+, Mg
2+
or Ca
2+
;
m is an integer from 1 to 10, preferably from 1 to 6,
n is an integer from 1 to 9, preferably from 1 to 3, and the ratio m:n is from 1:1 to 6:1, preferably 1:1 to 5:3 and particularly preferably 1:1, 4:3 or 2:1; and
x is zero, 1 or 2, preferably zero or 1.
In the Examples which follow, the numbers in brackets indicate the ratio (m+n:m) in each case. Examples of compounds of formula (I) are: 2-propylpentanoic acid (2:1) sodium salt; 2-propylpentanoic acid (2:1) sodium salt monohydrate and dihydrate; 2-propylpentanoic acid (3:2) sodium salt; 2-propylpentanoic acid (4:3) sodium salt; 2-propylpentanoic acid (4:3) sodium salt monohydrate; 2-propylpentanoic acid (5:3) sodium salt; 2-propylpentanoic acid (7:6) sodium salt and the monohydrate and dihydrate; preferably 2-propylpentanoic acid (m+n:m) sodium salt xH
2
O in which m+n is an integer from 3 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) lithium salt; 2-propylpentanoic acid (2:1) lithium salt monohydrate and dihydrate; 2-propylpentanoic acid (4:3) lithium salt; 2-propylpentanoic acid (4:3) lithium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) lithium salt xH
2
O in which m+n is an integer from 2 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) potassium salt; 2-propylpentanoic acid (2:1) potassium salt monohydrate; 2-propylpentanoic acid (3:2) potassium salt; 2-propylpentanoic acid (4:3) potassium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) potassium salt xH
2
O in which m+n is an integer from 2 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) rubidium salt; 2-propylpentanoic acid (2:1) rubidium salt monohydrate; 2-propylpentanoic acid (3:2) rubidium salt; 2-propylpentanoic acid (4:3) rubidium salt monohydrate; 2-propylpentanoic acid (m+n:m) rubidium salt xH
2
O in which m+n is an integer from 2 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; preferably 2-propylpentanoic acid (2:1) magnesium salt; 2-propylpentanoic acid (2:1) magnesium salt monohydrate; 2-propylpentanoic acid (3:2) magnesium salt; 2-propylpentanoic acid (4:3) magnesium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) magnesium salt xH
2
O in which m+n is an integer from 3 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) calcium salt; 2-propylpentanoic acid (2:1) calcium salt monohydrate; 2-propylpentanoic acid (3:2) calcium salt; 2-propylpentanoic acid (4:3) calcium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) calcium salt xH
2
O in which m+n is an integer from 3 to 10, m is 1 to (m+n−1) in each case and x is zero, one or two; 2-propylpentanoic acid (2:1) strontium salt; 2-propylpentanoic acid (2:1) strontium salt monohydrate; 2-propylpentanoic acid (3:2) strontium salt; 2-propylpentanoic acid (4:3) strontium salt monohydrate; preferably 2-propylpentanoic acid (m+n:m) strontiu
Cilag AG
Hoffmann & Baron , LLP
Raymond Richard L.
Tucker Zachary C.
LandOfFree
Method of preparing valproinic acid compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of preparing valproinic acid compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of preparing valproinic acid compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3311354